Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

Nabriva Therapeutics (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced its financial results for the three months ended March 31, 2018 and recent corporate highlights.

As quoted in the press release:

“Nabriva expects to report topline results from LEAP 2, our second pivotal Phase 3 trial evaluating oral lefamulin in adult patients with moderate CABP this spring. Subject to the receipt of positive data from LEAP 2, we plan to file an NDA for lefamulin with the U.S. Food and Drug Administration in the fourth quarter of this year and an MAA with the European Medicines Agency a few months later,” said Dr. Colin Broom, chief executive officer of Nabriva Therapeutics. “We have further prioritized our planned pre-commercial activities and anticipate that our current cash resources will be sufficient to fund our operations beyond a potential mid-2019 NDA approval and into the first quarter of 2020. Our highly experienced anti-infectives team, including medical affairs, market access and commercial professionals, will continue to focus on critical pre-launch activities. Our priority is to increase awareness of the burden of CABP in the medical community and identify institutions that have a high unmet medical need and could benefit from lefamulin should it be approved.”

Click here to read the full press release.